Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview

Abstract

Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density lipoprotein. The fact the agent is a monoclonal antibody has led to limited drug interactions and minimized adverse drug events. It is critical for all providers to have a basic understanding of these novel therapies with their introduction and use for treatment.

Keywords: Hyperlipidemia; Low-density lipoprotein; Proprotein convertase subtilisin/kexin type 9; Proprotein convertase subtilisin/kexin type 9 inhibitors.